RARRES2 and COVID-19: Increased concentration of chemerin were already observed in many other inflammatory conditions and the levels observed in the COVID-19 patients of our cohort (ranging from 125.1 to 149.4 ng/mL) are in line with those observed in rheumatoid arthritis (154 ng/mL (35)), psoriasis (125.3-196 ng/mL) (32, 33, 36), Crohn’s disease (140 ng/mL) (12), ulcerative colitis (124 ng/mL) (12), type 2 diabetes (144 ng/mL) (37) and acute myocardial infarction (173.8 ng/mL) (34).